During the past decade, Oncologic Dispensary No.2 conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 4 clinical trials were completed, i.e. on average, 19% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 1 clinical trials were completed. i.e. 8.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oncologic Dispensary No.2" #1 sponsor was "Janssen Research & Development, LLC" with 6 trials, followed by "Biocad" with 4 trials sponsored, "Amgen" with 2 trials sponsored, "BeiGene" with 2 trials sponsored and "BeyondSpring Pharmaceuticals Inc." with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oncologic Dispensary No.2" #1 collaborator was "Covance" with 1 trials as a collaborator, "Foundation Medicine" with 1 trials as a collaborator, "ICON plc" with 1 trials as a collaborator, "Pharmacyclics LLC." with 1 trials as a collaborator and "Sanofi" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Oncologic Dispensary No.2" are "Chemotherapy-induced Neutropenia" (2 trials), "Chemotherapy-induced Thrombocytopenia" (2 trials), "Chronic Lymphocytic Leukemia" (2 trials), "Follicular Lymphoma" (2 trials) and "Small Lymphocytic Lymphoma" (2 trials). Many other conditions were trialed in "Oncologic Dispensary No.2" in a lesser frequency.

Most popular intervention types in "Oncologic Dispensary No.2" are "Drug" (20 trials), "Biological" (4 trials) and "Other" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Fostamatinib disodium" (2 trials), "Niraparib" (2 trials), "Paclitaxel" (2 trials) and "Pegfilgrastim" (2 trials). Other intervention names were less common.

The vast majority of trials in "Oncologic Dispensary No.2" are 18 trials for "All" genders, 4 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Oncologic Dispensary No.2". undefined are not yet recruiting, 5 are recruiting, 6 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 11 completed trials in Oncologic Dispensary No.2, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Oncologic Dispensary No.2, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".